Jump to content

MK-886

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 23:16, 30 November 2019 (Removed URL that duplicated unique identifier. Removed accessdate with no specified URL. | You can use this bot yourself. Report bugs here.| Activated by User:Nemo bis | via #UCB_webform). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

MK-886
Skeletal formula of L 663536
Space-filling model of the L 663536 molecule
Names
IUPAC name
3-[3-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-propan-2-yl-indol-2-yl]-2,2 -dimethyl-propanoic acid
Other names
L-663536
Identifiers
MeSH L+663536
Properties
C27H34ClNO2S
Molar mass 472.083
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

MK-886, or L-663536, is a leukotriene antagonist. It may perform this by blocking the 5-lipoxygenase activating protein (FLAP), thus inhibiting 5-lipoxygenase (5-LOX),[1] and may help in treating atherosclerosis.[2]

References

  1. ^ Jun, Joon-Il; Lau, Lester F. (July 2010). "The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing". Nature Cell Biology. 12 (7): 676–685. doi:10.1038/ncb2070. ISSN 1465-7392. PMC 2919364. PMID 20526329.
  2. ^ Jawien, J.; Gajda, M.; Rudling, M.; Mateuszuk, L.; Olszanecki, R.; Guzik, T. J.; Cichocki, T.; Chlopicki, S.; Korbut, R. (March 2006). "Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice". European Journal of Clinical Investigation. 36 (3): 141–146. doi:10.1111/j.1365-2362.2006.01606.x. PMID 16506957.